New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...
In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...
The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...
A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent ...
Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.
13don MSN
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...
Women taking the drug tell the BBC it has given them their lives back.
Though it's rare and accounts for just 3% of all cancer cases, pancreatic cancer is one of the leading causes of death from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results